Corporation
AstraZeneca Canada Inc.
- Meetings this Parliament
- 63
- With MPs
- 19
- Since Nov 2021
- 134
- Active registrations
- 1
Most recent reported meeting: Aug 28, 2026.
Lobbying by AstraZeneca Canada Inc.: its registrations, its lobbyists, the bills it has named and every meeting it has reported with federal office holders since November 2021.
← LobbyingRegistrations in effect
In-house (corporation) In effect since May 11, 2026
Filed by Gaby Bourbara, President
Lobbyists
- Alex Romanovschi · Vice President, Scientific Affairs
- Carlo Mastrangelo · Head - Corporate Communications - Corporate Affairs Canada
- Deb Wong · Director, Payer Engagement
- Denise Lacombe · Head of Legal
- Gena Restivo · VP, Corporate Affairs & Sustainability
- Heather McDonald · Vice President, Market Access and Pricing
- Isabelle Gagnon · Lead - Federal Government Affairs
- Jon Feairs · Director, Government Affairs & Public Policy
- Noel Saraza · Senior Manager, Payer Relations
- Pascal Soriot · Chief Executive
- Tharany Ganesh · Head of Regulatory Affairs
Institutions they may lobby: Agriculture and Agri-Food Canada (AAFC), Atlantic Canada Opportunities Agency (ACOA), Canada Economic Development for Quebec Regions, Canada Foundation for Innovation, Canada Revenue Agency (CRA), Canadian Institutes of Health Research (CIHR), Canadian International Trade Tribunal (CITT), Canadian Northern Economic Development Agency (CanNor), Competition Bureau Canada (COBU), Federal Economic Development Agency for Southern Ontario (FedDev), Finance Canada (FIN), Global Affairs Canada (GAC), Health Canada (HC), House of Commons, Indigenous Services Canada (ISC), Innovation, Science and Economic Development Canada (ISED), Intergovernmental Affairs Secretariat (IGA), International Development Research Centre (IDRC), National Defence (DND), National Research Council (NRC), Natural Sciences and Engineering Research Council (NSERC), Patented Medicine Prices Review Board (PMPRB), Prime Minister's Office (PMO), Privy Council Office (PCO), Public Health Agency of Canada (PHAC), Public Services and Procurement Canada (PSPC), Royal Canadian Mounted Police (RCMP), Senate of Canada, Treasury Board Of Canada Secretariat (TBS), Veterans Affairs Canada (VAC)
What they're lobbying on (14)Hide details
- Public health and prevention programs including the Public Health Agency of Canada and efforts to support the development and procurement of innovative vaccines and therapies to address major public health issues such as pandemic preparedness and RSV
- Federally-funded public drug plans, including the Non-Insured Health Benefits program, Canadian Armed Forces Drug Benefit List and veteran programs, with respect to reimbursement for drug products for beneficiaries
- Canada's Drug Agency policies and processes as it relates to reimbursement recommendation decision-making process and framework
- Engage with Canadian government officials to discuss and provide input on Canada’s countermeasures and policies in response to foreign tariffs affecting the pharmaceutical industry, as well as free trade agreements as they relate to the biopharmaceutical industry
- Establish accountability with Health Canada, Canada’s Drug Agency and the pan-Canadian Pharmaceutical Alliance, as well as Regulations, policies and programs related to the review and reimbursement processes
- Patented Medicines (Notice of Compliance) Regulations as it relates to the regulation of intellectual property for biopharmaceutical products
- Patent Act as it relates to reporting requirements and pricing guidelines, and the protection of intellectual property in biopharmaceutical products
- Policy measures to ensure security of drug supply in Canada and preserve Canada’s attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations
- Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes
- Biomanufacturing and Life Sciences Strategy (BLSS) as it relates to the biopharmaceutical industry
- Pharmaceutical pricing policy issues arising from the jurisdiction of the Patented Medicines Prices Review Board (PMPRB)
- Engagement with the Government regarding the Strategic Response Fund (SRF) (previously known as SIF) and investment in Canada
- Annual federal Budgets and Budget updates relating to the biopharmaceutical industry.
- Scientific Research and Experimental Development (SR&ED) Tax Incentive Program regarding eligible expenditures. Discussions on policies such as "patent box" and Investment Tax Credits.
Registration 957438-15042-67. Look it up in the official Registry
Reported meetings
SpreadsheetFiled by Gaby Bourbara (91), Kiersten Combs (43).
-
Reported by Kiersten Combs · In-house (corporation)
- David Lee · Assistant Deputy Minister, Health Canada (HC)
- Ed Morgan · Director General, Health Canada (HC)
Health
-
Reported by Kiersten Combs · In-house (corporation)
- Corey Tochor · Member of Parliament
- James Hawkes · Parliamentary Assistant, House of Commons
HealthIndustry
-
Reported by Kiersten Combs · In-house (corporation)
- Francesco Sorbara · Member of Parliment, House of Commons
Health
-
Reported by Kiersten Combs · In-house (corporation)
- Stephen Ellis · Member of Parliament, House of Commons
Health
-
Reported by Kiersten Combs · In-house (corporation)
- Peter Schiefke · Member of Parliament
Health
-
Reported by Kiersten Combs · In-house (corporation)
- Michelle Boudreau · Executive Director, Health Canada (HC)
- Samir Khan · Associate Executive Director, Health Canada (HC)
Health
-
Reported by Kiersten Combs · In-house (corporation)
- Stephen Ellis · Member of Parliament, House of Commons
Health
-
Reported by Kiersten Combs · In-house (corporation)
- Emmanuelle Lamoureux · Director General Healthcare Strategies, Health Canada (HC)
- Julie Robert · Director | Data and analytics & Appropriate Prescribing and Use, Health Canada (HC)
HealthIndustry
-
Reported by Kiersten Combs · In-house (corporation)
- Andy Fillmore · Member of Parliament, House of Commons
- Rodrigo Arancibia · Director for Innovation, Science and Economic Development, Innovation, Science and Economic Development Canada (ISED)
Economic Development
-
Reported by Kiersten Combs · In-house (corporation)
- Daniel MacDonald · Director General, Health Canada (HC)
Health
-
Reported by Kiersten Combs · In-house (corporation)
- Daniel MacDonald · Director General, Health Canada (HC)
- Ed Morgan · Director General, Health Canada (HC)
- Bianca Hossain · Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
HealthIndustry
-
Reported by Kiersten Combs · In-house (corporation)
- Peter Fonseca · Member of Parliament
- Jean-Yves Duclos · Minister of Health, Health Canada (HC)
- Kamal Khera · Minister of Seniors, House of Commons
Health
-
Reported by Kiersten Combs · In-house (corporation)
- Ben Chin · Policy Advisor, Prime Minister's Office (PMO)
- Udita Samuel · Policy Advisor, Prime Minister's Office (PMO)
- Mark Kachuk · Special Assistant, Prime Minister's Office (PMO)
HealthResearch and Development
-
Reported by Kiersten Combs · In-house (corporation)
- Jean-Sebastien Bock · Director of Policy, Health Canada (HC)
- Sadenga Yeba · Deputy Director of Policy, Health Canada (HC)
- Shanzae Khan · Policy Advisor, Health Canada (HC)
Economic DevelopmentResearch and Development
-
Reported by Kiersten Combs · In-house (corporation)
- Rodrigo Arancibia · Director for Innovation, Science and Economic Development, Innovation, Science and Economic Development Canada (ISED)
- Craoline Menard · Manager, Innovation, Science and Economic Development Canada (ISED)
Economic Development
-
Reported by Kiersten Combs · In-house (corporation)
- Jean-Yves Duclos · Minister of Health, Health Canada (HC)
- Jean-Sebastien Bock · Director of Policy, Health Canada (HC)
- Sandenga Yeba · Senior Policy Advisor, Health Canada (HC)
Economic DevelopmentHealth
-
Reported by Kiersten Combs · In-house (corporation)
- Sandenga Yeba · Senior Policy Advisor, Health Canada (HC)
HealthResearch and Development
-
Reported by Kiersten Combs · In-house (corporation)
- Yash Nanda · Policy Advisor, Finance Canada (FIN)
Industry
-
Reported by Kiersten Combs · In-house (corporation)
- Michelle Boudreau · Executive Director, Health Canada (HC)
Industry
-
Reported by Kiersten Combs · In-house (corporation)
- Darryl Patterson · Director General, Innovation, Science and Economic Development Canada (ISED)
- Kasondra White · Director General, Innovation, Science and Economic Development Canada (ISED)
Industry
-
Reported by Kiersten Combs · In-house (corporation)
- Michelle Boudreau · Executive Director, Office of Pharmaceuticals Management Strategies, Health Canada (HC)
- Michelle Mujoomdar · Director, Specialty Pharmaceuticals, Health Canada (HC)
HealthResearch and Development
-
Reported by Kiersten Combs · In-house (corporation)
- Simon Kennedy · Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
HealthIndustryIntellectual PropertyInternational TradeScience and Technology
-
Reported by Kiersten Combs · In-house (corporation)
- Stephen Lucas · Deputy Minister, Health Canada (HC)
- Nancy Hamzawi · Federal Lead and Assistant Deputy Minister, Health Canada (HC)
HealthIndustryIntellectual PropertyInternational TradeScience and Technology
-
Reported by Kiersten Combs · In-house (corporation)
- Michelle Boudreau · Executive Director, Office of Pharmaceuticals Management Strategies, Health Canada (HC)
HealthIndustry
-
Reported by Kiersten Combs · In-house (corporation)
- Jean-Sebastien Bock · Director of Policy, Health Canada (HC)
- Sandenga Yeba · Senior Policy Advisor, Health Canada (HC)
Health
From the Office of the Commissioner of Lobbying's open data, published November 5, 2026. Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month. Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means. Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence. PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.